Form 4: Stoke Therapeutics Executive Huw M. Nash Sells Shares Under 10b5-1 Plan

Huw M. Nash, Chief Business Officer of Stoke Therapeutics, sold shares of common stock on July 2, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On July 2, 2024, Huw M. Nash, the Chief Business Officer of Stoke Therapeutics, sold 2,500 shares of common stock.
• The sales were executed under a Rule 10b5-1 trading plan adopted on December 29, 2023.
• The shares were sold at a weighted average price of $13.101, in a range from $12.83 to $13.74 per share.
• Additionally, 33 shares were sold at $13.90.
• The reported transactions also include 2,500 shares acquired through the Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: The document is neutral as it reports a routine stock sale under a pre-arranged plan. It doesn't inherently indicate positive or negative sentiment.

Industry Context

Executive stock sales are a common occurrence, and the use of 10b5-1 plans allows insiders to sell shares without being accused of acting on non-public information. The market will often look at the ratio of buys to sells to determine sentiment.

Stakeholder Impact

• The stock sale could have a minor impact on shareholders, depending on market perception of insider selling activity.

Key Dates